Deferoxamine and pioglitazone, FDA-approved drugs for the treatment of iron overload and diabetes, respectively, demonstrated a positive effect on the reduction of ROS level in dystrophin-deficient cardiomyocytes; therefore, we believe that it would be beneficial to continue the studies to validate their effectiveness and safety in the context of DMD. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.